RTM receives marketing authorisation for Fludeoxyglucose (18F)
We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018.
Fludeoxyglucose (18F) RTM 200 MBq/ml, solution for injection will become commercially available in The Netherlands in October, with roll-out to Belgium and Germany planned in 2019.
- Interesting? Share this article
Other news
Cooperation RTM-Alliance Medical
It is with great pleasure that we announce our cooperation with Alliance Medical Group (AMG) regardi...
First Patient Dosed with TLX250-CDx in Italy for ccRCC
The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...
18F-FDOPA now available
Fluorodopa (18F) is now available for clinical studies and - with doctor's certificate - for routine...
Upcoming event
From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress o...
Interested in a collaboration?
Contact us to discuss the possibilities.